Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

Sehr, Tony; Proschmann, Undine; Thomas, Katja; Ziemssen, Tjalf

Sehr, Tony; Proschmann, Undine; Thomas, Katja; Ziemssen, Tjalf.

Afiliación

Sehr T; MS Center, Center of Clinical Neurosciences, Department of Neurology, University Hospital Carl Gustav Carus, Dresden, Germany.
Proschmann U; MS Center, Center of Clinical Neurosciences, Department of Neurology, University Hospital Carl Gustav Carus, Dresden, Germany.
Thomas K; MS Center, Center of Clinical Neurosciences, Department of Neurology, University Hospital Carl Gustav Carus, Dresden, Germany.
Ziemssen T; MS Center, Center of Clinical Neurosciences, Department of Neurology, University Hospital Carl Gustav Carus, Dresden, Germany.

Mult Scler ; 24(6): 820-822, 2018 05.

Article en En | MEDLINE | ID: mdl-28805095

Asunto(s)

Esclerosis Múltiple Recurrente-Remitente; Esclerosis Múltiple; Humanos; Natalizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google